This information is not intended for US residents
CARDIOLOGY
TEVETEN® (eprosartan [mesylate])
The continuous dedication to the development and improvement of antihypertensive therapy lead to the development of the Angiotensin Receptor Blockers, the fastest growing class of antihypertensives. Since 1999 Solvay Pharmaceuticals has one of these agents: TEVETEN®. The active compound is eprosartan. TEVETEN® is a member of a new class of anti-hypertensive agents called angiotensin II receptor antagonists. As a class, these agents have been shown to be better tolerated than other types of medication for high blood pressure – an important consideration for the treatment of what generally is a symptomless disease. TEVETEN® may provide other benefits, as well. In registration trials involving more than 2,300 patients, TEVETEN® 600 mg taken once a day has been shown to reduce blood pressure effectively. Furthermore, TEVETEN® has been shown to be effective regardless of patient age, gender, race, or severity of disease. Adverse events were comparable between TEVETEN®- and placebo-treated patients, and TEVETEN® has so far shown no drug interaction. TEVETEN® has an additional effect. It modulates the negative effects of increased sympathetic nervous system activity, another key element in hypertension.
| generic name | |
| brandnames | |
| product description | |
| indications | |
| description of indications | |
| worldwide availability | |
| date and country of first launch | |
| average dosages | |
| links |
generic name
eprosartan [mesylate]
[back to top]
brandnames
TEVETEN®
[back to top]
product description
TEVETEN® (eprosartan) is a member of a new class of high blood pressure medicines called angiotensin II receptor blockers (ARBs), which act specifically on the receptor that triggers increased blood pressure. These drugs have been shown to be better tolerated than other types of medication for high blood pressure.
[back to top]
indications
Essential hypertension
[back to top]
description of indications
Essential hypertension
Hypertension is high blood pressure or a pressure higher than 140/90 mmHg . Essential hypertension is the most common cardiovascular disorder. In general about 20-25% of the population have high blood pressure, of which only about one in five are receiving adequate treatment. High blood pressure is a ‘silent disease’ and usually has no clear symptoms. Many people have high blood pressure for years without knowing it. Untreated high blood pressure can cause damage to the heart, brain, kidney, and arteries. It also increases the risk of heart attack, heart failure, kidney failure and stroke.
[back to top]
worldwide availability
TEVETEN® (eprosartan) is available in more than 40 countries worldwide, including all European countries and the United States.
[back to top]
date and country of first launch
After acquiring TEVETEN® from SmithKline Beecham in 1999, Solvay Pharmaceuticals first launched TEVETEN® in the same year in the US.
[back to top]
average dosages
The daily dosage of TEVETEN® (eprosartan) is 600 mg once daily. In some market places 300 and 400 mg tablets will be available for special cases.
[back to top]
Links
http://www.teveten.com